RCTJadad 1/5RandomizedPlacebo-Controlled

Creatine Timing for Strength: Why "2 Hours Before Training" Beat During and After in This Pilot Trial

NutrientsJune 1, 2026Vol. 18 (11)

Summary

If you already take creatine, you've probably wondered whether it matters if you drink it before, during, or after your workout. A new pilot study published in Nutrients (June 2026) tackled this question head-on — and its top-line finding cuts against a lot of "take it post-workout" advice you've seen on supplement labels and forums.

Researchers had 11 physically active men (average age 26) complete five separate strength-training sessions, each preceded by a different supplementation strategy: creatine taken as a single dose 2 hours before training (CrB), creatine split into small sips between sets during training (CrD), creatine taken immediately after training (CrF), a placebo (cornstarch) taken on the same before-training schedule as CrB, and a no-supplement control. Each participant cycled through all five conditions (a "crossover" design), with a week's washout between sessions, so each man effectively served as his own control. The creatine dose was modest and practical — 0.1 g per kg of body mass (about 8g for an 83kg man) as a single acute dose, with no multi-day loading phase.

The headline result: taking creatine 2 hours before lifting produced the best bench press and back squat performance (measured as total weight lifted across six sets at 80% of 1-rep max) of all five conditions — outperforming placebo, the no-supplement control, and even the during- and after-exercise creatine timings on the squat. The effect sizes were small-to-moderate (Cohen's d roughly 0.2–0.6), and the study's authors suspect the mechanism is that peak blood creatine levels coincide with the surge in muscle blood flow that happens during exercise, potentially improving delivery to working muscle.

Curiously, the "during" and "after" creatine conditions weren't clearly better than plain water or no supplement at all for squat performance, and jump power, cognitive performance, mood, perceived exertion, and muscle soreness were unaffected by timing. Blood tests showed creatine kinase (a muscle-stress marker) was modestly higher after post-workout creatine, and creatinine (a kidney-function marker) was lowest in the before-workout group — neither considered clinically concerning, and no adverse events occurred.

This adds a new wrinkle to the ongoing "creatine timing" debate, where prior chronic (multi-week) studies have found mixed results — some favoring post-workout dosing for muscle growth, others favoring pre-workout, and ISSN's most recent guidance treats timing as a minor factor compared to daily consistency. This is the first study to test acute, single-dose timing across three points (before/during/after) rather than just two, but with just 11 men, it's a starting point, not a verdict.

What This Means For You

If your main goal on a given day is maximizing acute strength performance (a big lift, a max-effort session, a competition), this study suggests taking your creatine dose about 2 hours before training rather than sipping it during your workout or saving it for after. A practical dose to mirror the study would be roughly 0.1 g/kg body mass (about 7–9g for most adults) mixed in water, though most commercial creatine monohydrate products use a flat 3–5g serving — check your label and consider whether scaling to body weight makes sense for you.

Importantly, this was a single acute dose without a loading phase, which is not how most people actually use creatine long-term. If you're using creatine as a daily supplement to build muscle and strength over weeks or months (the far more common use case), the bigger body of evidence still says consistency matters more than clock-watching: take your 3–5g daily, any time that fits your routine, and don't stress about hitting an exact pre- or post-workout window. Some longer studies actually favor post-workout dosing for muscle mass gains specifically, so this trial shouldn't be read as overturning that.

Who might care most about this finding: competitive lifters or athletes with a single important session (a meet, a test day) who want to optimize same-day output, and anyone curious about the physiology of nutrient timing. Who should be cautious: this doesn't apply to women, older adults, elite/highly trained athletes, or people with sedentary lifestyles, since the sample was young, physically active men only. As always, people with pre-existing kidney or liver conditions should talk to a doctor before starting creatine, and vegetarians/vegans (who typically have lower baseline creatine stores) may respond differently than the omnivorous participants studied here.

Important Considerations

This is explicitly a pilot study — the authors say so themselves — with only 11 participants, all young, physically active men. That's a small enough sample that individual differences (some people respond much more to creatine than others, based on baseline muscle creatine stores and fiber type) could meaningfully swing the group averages. Effect sizes were mostly small-to-moderate, and several important secondary outcomes (jump power, cognitive performance, RPE) trended toward but didn't reach statistical significance, which the authors note could reflect real "no effect" or simply not enough statistical power to detect one — a classic Type II error risk.

Blinding was only fully achieved for the pre-exercise creatine-vs-placebo comparison; participants necessarily knew when they were taking creatine during or after their workout (there was no matched placebo for those timings), so expectancy effects can't be ruled out for those comparisons. This weakens confidence in claims like "during-exercise creatine beat placebo." A formal Jadad quality score for this trial came out very low (1 out of 5), reflecting the incomplete blinding and lack of detailed dropout reporting — a signal to treat the findings as hypothesis-generating rather than conclusive.

The single acute dose (no loading phase) doesn't reflect how creatine is used in real life by most consumers, who take it daily for weeks or months. A 7-day washout between conditions may not have fully cleared creatine from muscle (full clearance can take 4–6 weeks), so some carryover between test sessions is possible. Diet wasn't controlled beyond asking participants to eat normally. Watch for any marketing that cites this single small trial as definitive proof that "pre-workout creatine timing is superior" — the authors themselves call for confirmation in larger, more rigorously blinded studies before drawing firm conclusions.

Terms Explained

Creatine monohydrateThe most researched and common form of creatine supplement, used to increase muscle energy stores (phosphocreatine) and support strength and power performance.

1-RM (one-repetition maximum)The heaviest weight a person can lift for a single repetition of an exercise; often used to set training loads as a percentage (e.g., 80% of 1-RM).

Crossover trialA study design where each participant receives every tested condition (in randomized order), letting researchers compare treatments within the same person rather than between separate groups.

Washout periodA gap between treatment conditions in a crossover trial meant to let the effects of the prior treatment fade before the next one begins.

Creatine kinase (CK)An enzyme released into the blood when muscle tissue is stressed or damaged; commonly used as a rough marker of exercise-induced muscle strain.

CreatinineA waste product of creatine/phosphocreatine breakdown in muscle, cleared by the kidneys and often used as a marker of kidney function — though exercise and creatine supplementation can raise it without indicating kidney harm.

Loading phaseA short period (typically 5–7 days) of higher-dose creatine intake (~20g/day) used to saturate muscle creatine stores faster, usually followed by a lower daily maintenance dose (3–5g).

Countermovement jump (CMJ)A vertical jump test (dip down, then jump) used to measure lower-body power and explosiveness.

Effect size (Cohen's d)A standardized number describing how large a difference between conditions is, independent of sample size; small, moderate, and large effects are typically labeled around 0.2, 0.5, and 0.8 respectively.

Jadad scoreA 0–5 scale rating the methodological quality of a randomized trial based on randomization, blinding, and reporting of dropouts; higher scores indicate stronger, less bias-prone study design.

Technical Study Details

Study Design

RegistrationPan African Clinical Trials Registry (PACTR): PACTR202309597156293

Total Score

JADAD Quality Assessment

/ 5

評価詳細

Randomization

2 / 2

Is the study described as randomized?

Yes+1

Rationale: The article explicitly and repeatedly describes the study as "randomized" (e.g., in the abstract's methods description, the experimental design section title/text, and the discussion/conclusion), satisfying the criterion for Q1.

Is the method of randomization described and appropriate?

Yes+1

Rationale: The article explicitly describes the randomization method: a random number was generated for each participant using Microsoft Excel's RAND() function, and participants were ranked and allocated to condition sequences based on these random numbers, with block sizes specified. Computer-generated random numbers (Excel's RAND function) constitute an appropriate randomization method per Jadad criteria, and the method is clearly and specifically described.

Blinding

-1 / 2

Is the study described as double-blind?

No0

Rationale: The article never uses the term "double-blind" to describe its own study design. It is described only as a "randomized, placebo-controlled crossover trial." The methods mention an attempt to "ensure blinding success" via opaque containers, but the Discussion/limitations explicitly acknowledge that blinding was not achieved for the CrD and CrF conditions since participants were necessarily aware of supplement timing, further confirming the study was not designed or described as double-blind.

Is the method of blinding described and appropriate?

No-1

Rationale: Although the authors describe a blinding procedure (opaque, unmarked containers handled by an independent person) and matched placebo appearance for the pre-exercise condition, the placebo was only administered under one timing schedule (matching CrB). There was no placebo condition matched to the CrD (during-exercise, split dosing between sets) or CrF (immediately post-exercise) timing schedules. The authors themselves explicitly acknowledge in the Discussion that blinding was only effective for the pre-exercise comparison, and that participants in the CrD/CrF conditions were necessarily aware of the timing of supplementation (since there was no equivalent placebo administered during or after exercise), which "may have confounded blinding and expectancy effects." This means the double-blinding method was not appropriately implemented across all study arms/comparisons, so this does not meet the Jadad criterion for an appropriate blinding method.</rationale>

Dropouts/Withdrawals

0 / 1

Is there a description of dropouts and withdrawals?

No0

Rationale: The article only mentions accounting for "potential attrition" when determining the recruited sample size (a priori planning), but it does not report the actual number of withdrawals/dropouts that occurred during the study, nor reasons for any such withdrawals, for each treatment group. All results sections report data as if all 11 participants completed all five conditions, with no flow diagram, CONSORT flow chart data, or explicit statement of participant retention/loss. Therefore, no description of withdrawals/dropouts is provided.

Study Population

Sample Size11

Age RangeMean: 26.09 years

ConditionHealthy physically active men (acute resistance exercise/creatine timing study)

Inclusion Criteria

Non-smokers who did not consume alcohol or use anti-inflammatory medications during the experimental period or for at least one month before study commencement
Free from musculoskeletal injury
Demonstrated stable recovery status (Hooper Index subscale scores ≤4 or total score ≤16 for three consecutive days)

Interventions

Creatine monohydrate

Treatment

Dose0.1 g/kg body mass, diluted in 500 mL water

FrequencySingle acute dose per experimental condition

DurationAcute, single-dose (no loading phase); administered before, during, or after the exercise session depending on condition

Routeoral

Placebo (cornstarch maltodextrin)

Control

Dose0.1 g/kg body mass, diluted in 500 mL water

FrequencySingle dose

DurationAcute, single dose

Routeoral

No supplement control

Control

Outcomes

Outcome	Type	Effect	p-value
Bench Press Performance (total external load lifted)	Primary	-	0.035Significant
Back Squat Performance (total external load lifted)	Primary	-	<0.001Significant
Countermovement Jump - Power	Secondary	-	0.85
Countermovement Jump - Height	Secondary	-	0.29
Countermovement Jump - Strength	Secondary	-	0.57
Countermovement Jump - Speed	Secondary	-	0.39
Creatine Kinase (muscle damage marker)	Secondary	-	0.016Significant
Creatinine (renal function marker)	Secondary	-	0.001Significant
Lactate Dehydrogenase	Secondary	-	0.50
Alkaline Phosphatase	Secondary	-	0.057
Alanine Aminotransferase	Secondary	-	0.16
Aspartate Aminotransferase	Secondary	-	0.49
Sodium (Na+)	Secondary	-	0.16
Potassium (K+)	Secondary	-	0.29
POMS - Fatigue-Inertia	Secondary	-	0.15
POMS - Anger	Secondary	-	0.73
POMS - Vigor	Secondary	-	0.82
POMS - Confusion	Secondary	-	0.58
POMS - Depression	Secondary	-	0.44
POMS - Tension	Secondary	-	0.84
Cognitive Performance	Secondary	-	0.054
Rating of Perceived Exertion	Secondary	-	0.06
Perceived Recovery Status	Secondary	-	0.46
Delayed-Onset Muscle Soreness	Secondary	-	0.35

Safety

Dropout Rate0.0%

No adverse events were explicitly reported. Blood markers of muscle damage (CK, LDH, ALT, AST, ALP) and renal function (creatinine) plus electrolytes (Na+, K+) were assessed as safety-related exploratory outcomes. CK was higher under CrF vs. control and PL; creatinine was lower under CrB vs. CrD, CrF, and control. No other biochemical markers differed significantly across conditions. No participant dropouts were reported (n=11 completed all five conditions).

Conclusion

In physically active men, ingesting a single dose of creatine monohydrate (0.1 g/kg) before a strength training session (CrB) was associated with greater acute bench press and back squat performance than ingesting creatine during (CrD) or after (CrF) exercise, placebo, or no supplementation. Creatine timing did not affect countermovement jump performance, cognitive function (digit cancelation test), mood state (POMS), perceived exertion, perceived recovery, or DOMS. Acute biochemical changes were limited to higher creatine kinase under CrF and lower creatinine under CrB, with no changes in other muscle damage, hepatic, or electrolyte markers. These findings are exploratory (pilot study, n=11) and require confirmation in larger samples with more robust placebo/control structures; results should not be extrapolated to chronic creatine supplementation practices.

Limitations

Pilot trial with a small cohort (n=11) evaluated across five complex experimental conditions, limiting statistical power and generalizability.
Placebo effectively controlled for placebo-induced effects only in the pre-exercise ingestion condition; participants were necessarily aware of supplementation timing in CrD, CrF, and control conditions, potentially confounding blinding and expectancy effects.
No dietary control was implemented beyond asking participants to maintain habitual diet, so variability in nutritional intake may have influenced baseline creatine stores and metabolic responses.
No direct measurements of neuromuscular activation, muscle fiber morphology/recruitment, muscle protein turnover, satellite cell activity, growth factor signaling, hormonal responses, oxidative stress, or inflammatory markers were performed.
Muscle creatine content was not directly measured, limiting mechanistic interpretation of timing effects.
The 7-day washout period, while consistent with prior acute crossover designs, may not fully eliminate carryover effects since full normalization of intramuscular creatine stores may require 4-6 weeks.
A single acute dose without a loading phase may not replicate effects seen with chronic creatine supplementation protocols.
Substantial variability across several secondary/exploratory outcomes likely reduced sensitivity to detect small but meaningful effects, increasing risk of Type II error.
Findings are specific to physically active young men and should not be generalized to women, highly trained athletes, or less active individuals without further study.